93 related articles for article (PubMed ID: 17074379)
21. HIV-1 cross-neutralizing antibodies in German HIV-1-infected patients do not correlate with an antibody-binding pattern against different HIV-1 isolates.
Jurkiewicz E; Petry H; Sutor GC; Lang S; Schedel I; Hunsmann G
AIDS; 1995 Jan; 9(1):91-3. PubMed ID: 7893448
[No Abstract] [Full Text] [Related]
22. High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors.
Wang Q; Shang H; Han X; Zhang Z; Jiang Y; Wang Y; Dai D; Diao Y
Microbiol Immunol; 2008 Apr; 52(4):209-15. PubMed ID: 18426395
[TBL] [Abstract][Full Text] [Related]
23. Mother to child transmission of HIV-1 in a Thai population: role of virus characteristics and maternal humoral immune response.
Kittinunvorakoon C; Morris MK; Neeyapun K; Jetsawang B; Buehring GC; Hanson CV
J Med Virol; 2009 May; 81(5):768-78. PubMed ID: 19319941
[TBL] [Abstract][Full Text] [Related]
24. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.
Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H
Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently.
Kashi VP; Jacob RA; Paul S; Nayak K; Satish B; Swaminathan S; Satish KS; Ranga U
Vaccine; 2009 Nov; 27(48):6739-47. PubMed ID: 19744585
[TBL] [Abstract][Full Text] [Related]
26. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
Haynes BF; Montefiori DC
Expert Rev Vaccines; 2006 Aug; 5(4):579-95. PubMed ID: 16989638
[TBL] [Abstract][Full Text] [Related]
27. The antigenic tip GPGRAFY of the V3 loop on HIV-1 gp120: genetic variability and subtypes.
Dong XN; Wu Y; Ying J; Chen YH
Immunol Lett; 2005 Oct; 101(1):112-4. PubMed ID: 15913789
[TBL] [Abstract][Full Text] [Related]
28. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
Huskens D; Van Laethem K; Vermeire K; Balzarini J; Schols D
Virology; 2007 Apr; 360(2):294-304. PubMed ID: 17123566
[TBL] [Abstract][Full Text] [Related]
29. Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India.
Vidyavijayan KK; Cheedarala N; Babu H; Precilla LK; Sathyamurthi P; Chandrasekaran P; Murugavel KG; Swaminathan S; Tripathy SP; Hanna LE
Front Immunol; 2018; 9():2841. PubMed ID: 30619250
[No Abstract] [Full Text] [Related]
30. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma.
Humbert M; Antoni S; Brill B; Landersz M; Rodes B; Soriano V; Wintergerst U; Knechten H; Staszewski S; von Laer D; Dittmar MT; Dietrich U
Eur J Immunol; 2007 Feb; 37(2):501-15. PubMed ID: 17236253
[TBL] [Abstract][Full Text] [Related]
31. Novel HIV-1 long terminal repeat (LTR) sequences of subtype B and mosaic intersubtype B/C recombinants in North India.
Neogi U; Sood V; Goel N; Wanchu A; Banerjea AC
Arch Virol; 2008; 153(10):1961-6. PubMed ID: 18818865
[TBL] [Abstract][Full Text] [Related]
32. Neutralization kinetics of sensitive and resistant subtype B primary human immunodeficiency virus type 1 isolates.
Davis D; Donners H; Willems B; Ntemgwa M; Vermoesen T; van der Groen G; Janssens W
J Med Virol; 2006 Jul; 78(7):864-76. PubMed ID: 16721864
[TBL] [Abstract][Full Text] [Related]
33. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies.
Fournier C; Duverlie G; François C; Schnuriger A; Dedeurwaerder S; Brochot E; Capron D; Wychowski C; Thibault V; Castelain S
Virol J; 2007 Mar; 4():35. PubMed ID: 17397531
[TBL] [Abstract][Full Text] [Related]
34. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India.
Kulkarni SS; Lapedes A; Tang H; Gnanakaran S; Daniels MG; Zhang M; Bhattacharya T; Li M; Polonis VR; McCutchan FE; Morris L; Ellenberger D; Butera ST; Bollinger RC; Korber BT; Paranjape RS; Montefiori DC
Virology; 2009 Mar; 385(2):505-20. PubMed ID: 19167740
[TBL] [Abstract][Full Text] [Related]
35. Quantitation of HIV-1 RNA levels in plasma and CSF of asymptomatic HIV-1 infected patients from South India using a TaqMan real time PCR assay.
Kamat A; Ravi V; Desai A; Satishchandra P; Satish KS; Borodowsky I; Subbakrishna DK; Kumar M
J Clin Virol; 2007 May; 39(1):9-15. PubMed ID: 17368087
[TBL] [Abstract][Full Text] [Related]
36. Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody.
Verity EE; Williams LA; Haddad DN; Choy V; O'Loughlin C; Chatfield C; Saksena NK; Cunningham A; Gelder F; McPhee DA
AIDS; 2006 Feb; 20(4):505-15. PubMed ID: 16470114
[TBL] [Abstract][Full Text] [Related]
37. Broad neutralizing antibody response and genetic variation in HIV-1 env genes in Koreans with primary HIV-1 infections.
Shin BG; Kim SS; Kim GJ
Arch Virol; 2011 Mar; 156(3):465-72. PubMed ID: 21184245
[TBL] [Abstract][Full Text] [Related]
38. Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy.
Hu X; Hu Y; Zhao C; Gao H; Greene KM; Ren L; Ma L; Ruan Y; Sarzotti-Kelsoe M; Montefiori DC; Hong K; Shao Y
Sci Rep; 2017 Apr; 7():46308. PubMed ID: 28387330
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing.
Carter CC; Wagner GA; Hightower GK; Caballero G; Phung P; Richman DD; Pond SL; Smith DM
Virology; 2015 Jan; 474():34-40. PubMed ID: 25463602
[TBL] [Abstract][Full Text] [Related]
40. HIV-1 binding and neutralizing antibodies of injecting drug users.
Ouverney EP; Teixeira SL; Silva-de-Jesus C; Hacker MA; Morgado MG; Bastos FI; Bongertz V
Braz J Med Biol Res; 2005 Sep; 38(9):1313-20. PubMed ID: 16138213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
